Neoadjuvant SAbR shows promising outcomes in RCC with tumor thrombus

In total, the prospective phase 2 study included 23 patients with newly diagnosed RCC. Patients received neoadjuvant SAbR as 40 Gy over 5 fractions or 36 Gy over 3 fractions, followed by surgery. The median follow-up was 35.2 months.

Data showed…

Continue Reading